argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
970.43
-10.90 (-1.11%)
Nov 13, 2026, 12:11 PM EST - Market open
argenx SE Revenue
argenx SE had revenue of $1.75B in the quarter ending September 30, 2026, with 52.13% growth. This brings the company's total for the last twelve months to $5.93B, up 60.78% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth.
Revenue (ttm)
$5.93B
Revenue Growth
+60.78%
P/S Ratio
10.37
Revenue / Employee
$3,175,238
Employees
1,863
Market Cap
60.63B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full argenx SE breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | -15.91M | -32.14% |
| Dec 31, 2017 | 49.50M | 31.46M | 174.30% |
| Dec 31, 2016 | 18.05M | 7.24M | 66.96% |
| Dec 31, 2015 | 10.81M | 4.30M | 66.15% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | 3.23M | 80.71% |
| Dec 31, 2012 | 4.00M | 9.75K | 0.24% |
| Dec 31, 2011 | 3.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 16.90B |
| Vertex Pharmaceuticals | 12.95B |
| BeOne Medicines AG | 6.45B |
| Incyte | 6.01B |
| Genmab | 4.30B |
| BioNTech SE | 2.75B |
| Royalty Pharma | 2.62B |
| Moderna | 2.53B |
ARGX News
- 5 hours ago - Argenx price target lowered to $1,130 from $1,190 at Morgan Stanley - TheFly
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX - PRNewsWire
- 1 day ago - Roth Capital biotech analysts hold analyst/industry conference call - TheFly
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX - GlobeNewsWire
- 2 days ago - argenx SE Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 4 days ago - argenx SE Announces Agreement to Acquire Unnatural Products, Inc. for Up to Approximately $1.15 billion - Nasdaq
- 4 days ago - Argenx to acquire Unnatural Products for $1.15B - TheFly
- 4 days ago - 3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade - The Motley Fool